Profile data is unavailable for this security.
About the company
Windlas Biotech Limited is an India-based company that is primarily engaged in the manufacturing and trading of pharmaceutical products. The Company provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. It has capabilities for both solid and liquid pharmaceutical dosage forms. The Company markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. It also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
- Revenue in INR (TTM)6.00bn
- Net income in INR526.38m
- Incorporated2001
- Employees1.05k
- LocationWindlas Biotech Ltd40/1 Mohabewala Industrial AreaDEHARADUN 248110IndiaIND
- Websitehttps://windlas.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Panacea Biotec Ltd | 5.52bn | -119.17m | 8.58bn | 1.09k | -- | -- | 16.69 | 1.56 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.89bn | 1.06k | 41.77 | -- | 18.14 | 1.78 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 9.44bn | 940.00 | 38.41 | -- | 35.95 | 4.28 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
Windlas Biotech Ltd | 6.00bn | 526.38m | 11.43bn | 1.05k | 21.82 | -- | 17.28 | 1.90 | 25.18 | 25.18 | 286.98 | -- | -- | -- | -- | 5,723,394.00 | -- | -- | -- | -- | 37.06 | -- | 8.77 | -- | -- | 59.55 | -- | -- | 10.12 | -- | 11.91 | -- | -- | -- |
Vimta Labs Ltd | 3.20bn | 413.41m | 11.60bn | 1.37k | 28.47 | -- | 15.36 | 3.62 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 11.80bn | 38.00 | 125.35 | 45.43 | 131.43 | 26.21 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.97bn | 1.70k | 13.72 | -- | 12.27 | 2.18 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
Kopran Ltd | 5.79bn | 403.74m | 12.04bn | 394.00 | 30.03 | -- | 22.76 | 2.08 | 8.32 | 8.32 | 119.70 | -- | -- | -- | -- | 14,693,070.00 | -- | 8.64 | -- | 12.88 | 35.60 | 34.36 | 6.97 | 8.71 | -- | 36.80 | -- | -- | 15.38 | 11.85 | -55.38 | 5.86 | 39.08 | -- |
Bliss GVS Pharma Ltd | 7.57bn | 879.46m | 12.46bn | 763.00 | 14.38 | -- | 10.90 | 1.65 | 8.28 | 8.28 | 71.43 | -- | -- | -- | -- | 9,919,995.00 | -- | 7.72 | -- | 10.13 | 47.73 | 38.59 | 11.88 | 10.80 | -- | 10.26 | -- | 8.26 | 0.553 | 15.07 | 371.13 | 107.42 | 27.16 | -12.94 |
Beta Drugs Ltd | 2.56bn | 347.57m | 12.95bn | 315.00 | 37.27 | 9.12 | 28.30 | 5.06 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
Zota Health Care Ltd | 1.68bn | -100.65m | 12.96bn | 338.00 | -- | -- | 182.54 | 7.73 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
Syncom Formulations (India) Ltd | 2.50bn | 263.83m | 13.11bn | 799.00 | 41.03 | -- | 42.33 | 5.25 | 0.34 | 0.34 | 3.26 | -- | -- | -- | -- | 3,126,329.00 | -- | 7.69 | -- | 10.30 | 39.33 | 31.92 | 10.56 | 8.73 | -- | 4.72 | -- | -- | 2.09 | 7.17 | 1.42 | 18.34 | 25.48 | -- |
Hester Biosciences Ltd | 2.93bn | 184.70m | 14.39bn | 693.00 | 75.07 | -- | 36.64 | 4.92 | 22.54 | 22.54 | 352.21 | -- | -- | -- | -- | 4,222,078.00 | -- | 8.22 | -- | 10.27 | 67.10 | 69.31 | 7.00 | 16.15 | -- | 2.15 | -- | 22.67 | 13.23 | 14.30 | -32.28 | 0.7733 | 27.62 | -4.36 |
Holder | Shares | % Held |
---|---|---|
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2023 | 1.95m | 9.40% |
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 215.40k | 1.04% |
Macquarie Funds Management Hong Kong Ltd.as of 30 Nov 2021 | 20.45k | 0.10% |